Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors

Informazioni relative al progetto

RespiriTB

ID dell’accordo di sovvenzione: 853903

DOI 10.3030/853903

Data della firma CE 8 Maggio 2019

Data di avvio 1 Maggio 2019

Data di completamento 30 Aprile 2027

Finanziato da

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Costo totale € 9 962 900,00

Contributo UE € 6 840 000,00

Coordinato da

ACADEMISCH ZIEKENHUIS LEIDEN
Netherlands

Risultati finali

Documents, reports (3)

Purified Mtb cytochrome report

The Purified Mtb cytochrome report will describe the methodology and confirmation of the purified cytochrome bc1, bc1:aa3, and bd

Continuous enzymatic assay and screening report

The continuous enzymatic assay and screening report will describe the assay, conditions and characterisation methodology of the continuous enzymatic assay for testing Mtr inhibitors and the application in the High Throughput Screening campaign.

In vitro activity of single HDT compounds report

In vitro activity of single HDT compounds report will summarize the results of in vitro activity of single Host Directed Therapeutics compounds against intracellular MDRMtb strains in human cells

Websites, patent fillings, videos etc. (1)

Website RespiriTB online

The website developed for communication of all RespiriTB activities will be active and online.

Pubblicazioni

Non-peer reviewed articles (1)

Host‐directed therapy to combat mycobacterial infections*

Autori: Gül Kilinç, Anno Saris, Tom H. M. Ottenhoff, Mariëlle C. Haks
Pubblicato in: Immunological Reviews, Numero 301/1, 2021, Pagina/e 62-83, ISSN 0105-2896
Editore: Blackwell Publishing Inc.
DOI: 10.1111/imr.12951